
	Where results make sense

Topic: Dolasetron

In the News (Sat 19 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	Anzemet - Anzemet Side Effects - Anzemet Information - Canadian Pharmacy
		Dolasetron and its active metabolite, hydrodolasetron (MDL 74156), are selective 5-HT receptor antagonists shown not to have activity at other known serotonin receptors and with low affinity for dopamine receptors.
		However, dolasetron is not recommended in patients with severe renal impairment because of the possibility of prolonged QTc intervals and other cardiac conduction abnormalities from elevated hydrodolasetron levels.
		Dolasetron did not inhibit the antitumor activity of 4 chemotherapeutic agents (cisplatin, 5-fluorouracil, doxorubicin, cyclophosphamide) in 4 murine models.
	www.rxcanadapharmacy.com /htmfiles/Anzemet.asp?id=115 (2615 words)

	DARE abstract20031058 (Site not responding. Last check: 2007-10-20)
		For dolasetron, there were 35 patients in the 45 microg/kg dosage group, 32 in the 175 microg/kg group, 31 in the 350 microg/kg group, and 37 in the 700 microg/kg group.
		For dolasetron, the age of the patients according to dosage group was 6.1 (+/- 2.8) years in the 45 microg/kg group, 5.3 (+/- 2.5) years in the 175 microg/kg group, 6.5 (+/- 2.6) years in the 350 microg/kg group, and 6.1 (+/-2.5) years in the 700 microg/kg group.
		As the results of the study found that the two largest doses of dolasetron and the dose of ondansetron were more effective than the smallest dose of dolasetron, the authors argued that this supported the internal validity of their conclusions.
	nhscrd.york.ac.uk /online/nhseed/20031058.htm (1926 words)

	Anzemet Tablets Prescribing Information - Aventis Pharmaceuticals - February 2005 (Site not responding. Last check: 2007-10-20)
		Dolasetron mesylate and its active metabolite, hydrodolasetron (MDL 74,156), are selective serotonin 5-HT receptor antagonists not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors.
		The reduction of dolasetron to hydrodolasetron is mediated by a ubiquitous enzyme, carbonyl reductase.
		Dolasetron mesylate was not genotoxic in the Ames test, the rat lymphocyte chromosomal aberration test, the Chinese hamster ovary (CHO) cell (HGPRT) forward mutation test, the rat hepatocyte unscheduled DNA synthesis (UDS) test or the mouse micronucleus test.
	www.aventis-us.com /PIs/anzemet_TXT.html (3019 words)

	MedicineHouse.com
		Children: IV 0.35 mg/kg (max.12.5 mg) Dolasetron may be administered by direct IV injection (at a rate no greater than 100 mg/30 seconds) or as an intravenous infusion (dilute and administer over 15 mins).
		It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine and that the released serotonin then activates the 5-HT3 receptors located on vagal afferents to initiate the vomiting reflex.
		Dolasetron should be used with caution in patients who have or may develop prolongation of cardiac conduction intervals, particularly QTc.
	www.medicinehouse.com /cgi-bin/drug1.php?drug=dolasetron_mesylate (796 words)

	dolasetron of Augusta, Georgia
		Dolasetron blocks the actions of chemicals in the body that may cause nausea and vomiting.
		Dolasetron is used to prevent nausea and vomiting associated with cancer chemotherapy or surgery.
		Dolasetron is in the FDA pregnancy category B. This means that it is not expected to harm an unborn baby.
	www.universityhealth.org /16243.cfm (1089 words)

	Texas Medicaid Vendor Drug Program, Dolasetron (Anzemet®),Granisetron (Kytril®), Ondansetron(Zofran®) - ... (Site not responding. Last check: 2007-10-20)
		Oral dolasetron is approved for use in preventing chemotherapy-induced nausea and vomiting and prosoperstive nausea and vomiting.
		Dolasetron, granisetron, and ondansetron are NOT indicated for use in controlling general nausea and vomiting.
		Dolasetron should be administered with caution to patients receiving concurrent therapy with anti-arrhythmic agents or other drugs which lead to QT prolongation as the potential for cardiotoxicity is enhanced with this drug combination.
	www.hhsc.state.tx.us /HCF/vdp/Criteria/hydrx5ht.html (913 words)

	Dolasetron - Talk Medical
		Dolasetron can affect the way that your heart beats, which can be dangerous.
		Do not take Dolasetron without first talking to your doctor if you are pregnant or if you are planning a pregnancy.
		The mixture of Dolasetron and juice is good for up to 2 hours at room temperature.
	www.talkmedical.com /medications/1952/Dolasetron (637 words)

	Dolasetron prophylaxis reduces nausea and postanaesthesia recovery time after remifentanil infusion during monitored ...
		Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study.
		Oral dolasetron mesylate for prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study.
		Dolasetron for the prevention of postoperative nausea and vomiting following outpatient surgery with general anaesthesia: a randomized, placebo-controlled study.
	bja.oxfordjournals.org /cgi/content/full/90/2/194 (1768 words)

	5-Hydroxytryptamine3 (5-HT3) Receptor Antagonists
		Intravenous dolasetron mesilate in the prevention of postoperative nausea and vomiting in females undergoing gynecological surgery.
		Intravenous dolasetron mesylate ameliorates postoperative nausea and vomiting.
		Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer.
	pharmacy.oregonstate.edu /drug_policy/reviews-evaluations/hydroxytryptamine3.html (1608 words)

	MedlinePlus Drug Information: Dolasetron
		Dolasetron is used to prevent nausea and vomiting caused by cancer chemotherapy, anesthesia, or surgery.
		Dolasetron is in a class of medications called serotonin 5-HT receptor antagonists.
		Dolasetron comes as a tablet to take by mouth.
	www.nlm.nih.gov /medlineplus/druginfo/medmaster/a601001.html (562 words)

	A Comparison of Ondansetron and Dolasetron (Site not responding. Last check: 2007-10-20)
		The current thesis study was performed for the purpose of comparing ondansetron and dolasetron to one another in the prevention and treatment of PONV in an outpatient surgical population.
		Significant differences were seen in the use of dolasetron for prophylaxis, with a longer time to occurrence of PONV and for rescue treatment of established PONV, with a 0% need for further antiemetic treatment following single rescue doses.
		Dolasetron for the Prevention of Postoperatiave Nausea and Vomiting Following Outpatient Surgery With General Anaesthesia: A Randomized, Placebo-Controlled Study.
	fred.ccsu.edu:8000 /archive/00000058/02/etd-2003-14.html (10113 words)

	5-HT3 Receptor Antagonists and ECG Effects
		As dolasetron was the last of the three agents in clinical development, most of the trials involving dolasetron included specific ECG monitoring, resulting in more detailed ECG data for this compound.
		Specifically, dolasetron caused acute effects on the ECG via sodium channel blockade to delay ventricular depolarization, manifested as prolonged PR and QRS duration, without a substantial effect on ventricular repolarization (QT interval).
		Dolasetron, ondansetron, and granisetron also have, as a class, some effects on ECG intervals.
	www.clevelandclinicmeded.com /medical_info/pharmacy/novdec2002/5ht.htm (1656 words)

	Anzemet Online, Description, Chemistry, Ingredients - Dolasetron - RxList Monographs
		ANZEMET (dolasetron mesylate) is an antinauseant and antiemetic agent.
		Dolasetron mesylate monohydrate is a white to off-white powder that is freely soluble in water and propylene glycol, slightly soluble in ethanol, and slightly soluble in normal saline.
		Each ANZEMET Tablet for oral administration contains dolasetron mesylate (as the monohydrate) and also contains the inactive ingredients: carnauba wax, croscarmellose sodium, hydroxypropyl methylcellulose, lactose, magnesium stearate, polyethylene glycol, polysorbate 80, pregelatinized starch, synthetic red iron oxide, titanium dioxide, and white wax.
	www.rxlist.com /cgi/generic2/dolaset.htm (177 words)

	MedlinePlus Drug Information: Dolasetron (Systemic) (Site not responding. Last check: 2007-10-20)
		Dolasetron (dol-A-se-tron) is used to prevent and treat the nausea and vomiting that may occur after treatment with anticancer medicines (chemotherapy) or after surgery.
		When you are taking dolasetron, it is especially important that your health care professional know if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicines.
		The dose of dolasetron will be different for different patients.
	www.nlm.nih.gov /medlineplus/druginfo/uspdi/203375.html (1114 words)

	Nursing: New drugs 98, part IV: Dolasetron Mesylate
		Dolasetron mesylate (Anzemet, Hoechst Marion Roussel) joins ondansetron (Zofran) and granisetron (Kytril) as the third drug in its class.
		The oral formulation is indicated to prevent nausea and vomiting after surgery and after chemotherapy regimens that generally cause moderate nausea and vomiting.
		Dolasetron has been reported to cause electrocardiogram interval changes (for example, prolongation of the QTc interval), which may lead to arrhythmias.
	www.findarticles.com /p/articles/mi_qa3689/is_199807/ai_n8796380 (347 words)

	Drug Insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting : Nature Clinical Practice ...
		The first-generation 5-HT3 receptor antagonists (ondansetron, dolasetron, granisetron, and tropisetron) form the cornerstone of antiemetic therapy for moderately to highly emetogenic chemotherapy.
		In comparison, the half-lives of ondansetron and dolasetron are approximately 4 h and 8 h, respectively.
		Given the prolonged half-life of palonosetron (40 h) compared with ondansetron (4 h) and dolasetron (<8 h), it is not surprising that greater efficacy was noted in the delayed period with palonosetron in the moderately emetogenic trials.
	www.nature.com /ncponc/journal/v2/n4/full/ncponc0132.html (3006 words)

	Dolasetron (Systemic)
		Dolasetron has not been studied in pregnant women.
		It is not known whether dolasetron passes into the breast milk.
		Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are taking dolasetron.
	allnutritionals.com /drugs/d/dolasetron-systemic.shtml (1084 words)

	Palonosetron (Aloxi)
		Palonosetron, ondansetron, and dolasetron all have similar frequency and severity profiles with regard to adverse reactions.
		A comparison of the adverse events for palonosetron, ondansetron, and dolasetron that were observed in >2% of patients in the clinical trials is presented in Table 1.
		A 100 mg dose of IV dolasetron costs approximately $173, a 32 mg dose of IV ondansetron costs approximately $205, and a 1 mg dose of IV granisetron is approximately $195.
	uuhsc.utah.edu /pharmacy/bulletins/palonosetron.html (781 words)

	National Cancer Institute - Nausea and Vomiting
		Dolasetron IV should be given at 1.8 mg/kg as a single dose approximately 30 minutes before chemotherapy.
		The effectiveness of oral dolasetron in the prevention of chemotherapy-induced nausea and vomiting has been proven in a large randomized, double-blind, comparative trial of 399 patients.[33] Oral dolasetron was administered in the range of 25 to 200 mg 1 hour prior to chemotherapy.
		Based on the above studies, palonosetron was approved by the FDA in July, 2003 for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy; and for the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
	www.nci.nih.gov /cancertopics/pdq/supportivecare/nausea/HealthProfessional/page6 (6288 words)

	JournalClub Review - Oral dolasetron effective after moderately emetogenic chemotherapy (Site not responding. Last check: 2007-10-20)
		Single oral doses of dolasetron mesylate are safe and effective in preventing emesis in cancer patients receiving moderately emetogenic chemotherapy, according to a recent report from the U.S. Oral Dolasetron Dose-Response Study Group.
		That was the principal conclusion of the first multicentred trial to asses the comparative antiemetic efficacy and safety of dolasetron mesylate, a new type three 5-hydroxytryptamine (5-HT3) receptor antagonist, and ondansetron in the prevention of chemotherapy-induced emesis.
		Doses of 1.8 mg/kg dolasetron, 2.4 mg/kg dolasetron, or 32 mg ondansetron resulted in complete response rates of 49.2%, 45.6% and 50.4%, respectively, in the low-dose cisplatin group, and 36.8%, 31.3%, and 31.8%, respectively, in the high-dose cisplatin group.
	www.pslgroup.com /jclub6.HTM (588 words)

	Anzemet, Dolasetron Mesylate, Serotinin Inhibitor, Antiemetic, Prescription Drugs, Medications, Medicines (Site not responding. Last check: 2007-10-20)
		Dolasetron mesylate blocks the serotonin pathway by which chemotherapy stimulates the vomiting center in the brain.
		The first dose of dolasetron usually is taken in a hospital or clinic 30 minutes before chemotherapy is begun or 15 minutes before anesthesia is stopped.
		Dolasetron, Dosage and Administration:"ANZEMET Tablets are indicated for: 1) the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy, including initial and repeat courses; 2) the prevention of postoperative nausea and vomiting.
	www.buyxanaxonline.com /drugs/antiemetic.serotonin.inhibitor.anzemet.dolasetron.mesylate.htm (1643 words)

	A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy ...
		The safety and tolerability of dolasetron mesylate, a potent and selective 5-HT3 receptor antagonist, were evaluated after single intravenous doses in healthy male volunteers.
		Overall, the percentage of subjects reporting adverse events was similar in those receiving dolasetron (44/64; 68.8%) or placebo (10/16; 62.5%); most adverse events were mild in severity.
		Subjects receiving dolasetron reported a higher incidence of central nervous system (headache and dizziness/lightheadedness), gastrointestinal (increased appetite and nausea), and visual adverse events and taste alterations.
	jcp.sagepub.com /cgi/content/abstract/35/7/705 (409 words)

	mc2 - Company (Site not responding. Last check: 2007-10-20)
		Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting.
		dolasetron mesylate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients.
		A double-blind, randomized, parallel study of IV dolasetron mesylate versus IV metoclopramide in patients receiving moderately emetogenic chemotherapy.
	www.medcomco.com /companypubs.htm (769 words)

	The Cardiotoxic Potential of the 5-HT3 Receptor Antagonist Antiemetics: Is There Cause for Concern? -- Keefe 7 (1): 65 ...
		A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
		Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers.
		Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
	theoncologist.alphamedpress.org /cgi/content/full/7/1/65 (3618 words)

	Dolasetron (Site not responding. Last check: 2007-10-20)
		Dolasetron decreases nausea and vomiting caused by chemotherapy drugs.
		Dolasetron is also taken by mouth with or without food.
		Take the missed dose as soon as possible if you take dolasetron on a regular schedule and you skip or forget to take a dose by mouth.
	www.hci.utah.edu /patientdocs/hci/drugs/dolasetron.htm (262 words)

	Cancerquest: Dolasetron (Site not responding. Last check: 2007-10-20)
		Anzemet® (dolasetron mesylate) is used to the prevent nausea and vomiting associated with cytotoxic effects of chemotherapy.
		Dolasetron is administered in pill form or as in injection.
		The most common side effects associated with the use of Anzemet® during chemotherapy regimens are headache, fatigue and diarrhea.
	www.cancerquest.org /printfriendly.cfm?printpage=1313 (58 words)

	Cancer Spectrum: Medline Abstract (Site not responding. Last check: 2007-10-20)
		This multicentre, randomised, double-blind study was designed to compare the anti-emetic efficacy and safety of single oral doses of dolasetron mesilate with that of the approved oral, multiple-dose regimen of ondansetron in 399 cancer patients receiving moderately emetogenic chemotherapy.
		Single oral doses of 25, 50, 100 or 200 mg of dolasetron mesilate were administered 1 h prior to the initiation of moderately emetogenic chemotherapy.
		Multiple doses of ondansetron (8 mg x 3 or 8 mg x 4) capsules, or matching placebo for patients randomised to dolasetron, were given 1.5 h before and 6.5, 14.5 and 22.5 h after the start of chemotherapy (total dose = 32 mg).
	jncicancerspectrum.oxfordjournals.org /cgi/medline/pmid;8911112 (280 words)

Try your search on: Qwika (all wikis)